ResMed Inc.
Every calculator, already run for RMD
Open the full toolkit →You have the numbers on RMD. Get the argument.
A written report on which of these readings actually decide the outcome for ResMed Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering RMDAnalyst Price Target Disagreement for ResMed Inc.
Wall Street's bull case implies +43% from the current price; the bear case implies -22%. A 65% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for RMD
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ResMed Inc.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a clo…
RMD — frequently asked
Is RMD a buy right now?
Wall Street's consensus rating on ResMed Inc. is Buy across 19 analysts, with a mean price target of $247.56 (+11% vs. the current $223.61). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is RMD overvalued?
RMD trades at 21.4x trailing earnings, against a DCF fair value of $158 per share. The current price implies 10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is RMD's next earnings date?
ResMed Inc. is next scheduled to report earnings around Oct 29, 2026. A full RMD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ResMed Inc.?
Analysts covering ResMed Inc. (RMD) range from a bear-case target of $175.00 to a bull-case high of $320.00, with a mean consensus target of $247.56 across 16 analysts. The spread of $145.00 (65% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ResMed Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ResMed Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full RMD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ResMed Inc., in minutes. 3 free reports included with every account — no credit card required.